The molecular events and transcriptional plasticity that drive brain metastasis in clinically relevant breast tumor subtypes have not yet been elucidated. Recently, a study published in the journal Nature Communications titled “Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities” by scientists from RCSI University of Medicine and Health Sciences and other institutions revealed a potential new approach that could use existing drugs to target secondary breast cancer that has spread to the brain. The findings are expected to aid in the development of new treatments for breast cancer and cancer metastasis.

Most breast cancer-related deaths result from tumor recurrence that spreads to multiple other organs. When secondary breast cancer, known as metastatic breast cancer, spreads to the brain, it becomes extremely aggressive, leaving patients with a survival time of only a few months.

In this study, researchers focused on tracking how tumors evolve from the initial diagnosis of primary breast cancer to the point of metastatic spread to the brain. They found that nearly half of the tumors alter the way they repair DNA, making them more susceptible to existing drugs called PARP inhibitors, which work by inhibiting cancer cells from repairing their own DNA, leading to cancer cell death.

Study author Dr. Leonie Young noted that there are currently insufficient treatment options for breast cancer patients whose disease has spread to the brain, highlighting an urgent need for research focused on expanding treatment choices. This study represents a significant advancement, bringing researchers closer to developing potential new therapies for patients with this devastating complication of breast cancer. By identifying novel vulnerabilities in DNA pathways during brain metastasis, the researchers have opened the door to new therapeutic strategies for breast cancer patients who previously had limited targeted treatment options.

In summary, the findings provide evidence of functionally relevant homologous recombination deficiency at both the genomic and transcriptional levels, which contributes to genomic instability in breast cancer brain metastases—a finding with significant implications for potential clinical translation.